Salmeterol Monograph: Long-Acting Beta-2 Agonism, Asthma Combination Therapy and Safety

Evidence-informed pharmacology monograph. Reviewed 10 November 2026. Educational material only; clinical use requires current local product labeling and patient-specific assessment. Clinical overview Salmeterol is a long-acting beta-2 adrenergic receptor agonist (LABA) used for maintenance bronchodilation in selected asthma or COPD regimens. It provides a duration of bronchodilation of approximately 12 hours but has slower onset…

Read Full News

Misoprostol Monograph: PGE1 Analogue, Gastric Protection and Obstetric Applications

Evidence-informed pharmacology monograph. Reviewed 10 November 2026. Educational material only; clinical use requires current local product labeling and patient-specific assessment. Overview and correct classification Misoprostol is a synthetic prostaglandin E1 (PGE1) analogue used to prevent NSAID-associated gastric ulcers in appropriate patients and, under indication-specific obstetric/gynecologic protocols, for cervical ripening, uterine evacuation, medication abortion and postpartum…

Read Full News

Sumatriptan Monograph: 5-HT1B/1D Migraine Therapy, MAO-A Metabolism and Contraindications

Evidence-informed pharmacology monograph. Reviewed 10 November 2026. Educational material only; clinical use requires current local product labeling and patient-specific assessment. Overview and chemistry Sumatriptan is an indole-derived selective serotonin 5-HT1B/1D receptor agonist (a triptan) used for acute migraine treatment and, in injectable form, selected cluster headache attacks. It is not a drug for migraine prophylaxis….

Read Full News

Pentazocine: Mixed Opioid Agonist–Antagonist, Analgesia and Withdrawal Risk

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians. Overview and clinical role Pentazocine is a synthetic benzomorphan opioid analgesic with mixed agonist–antagonist properties, principally kappa-opioid receptor agonism and weak/partial mu-opioid activity. It has been used for pain severe enough to…

Read Full News

Buprenorphine: Partial Mu Agonism, Opioid Use Disorder Treatment and Pain Safety

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians. Overview Buprenorphine is a semisynthetic thebaine-derived opioid with high-affinity, partial agonist action at mu-opioid receptors and antagonist activity at kappa receptors. Depending on formulation and labeling, it treats opioid use disorder (OUD)…

Read Full News

Methadone: Full Mu Opioid Agonist, Long Half-Life, OUD Treatment and QT Risk

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians. Overview Methadone is a fully synthetic diphenylheptane opioid with full mu-opioid agonist activity, used for OUD treatment within regulated programs and, in separate labeled formulations, selected severe persistent pain. It is not…

Read Full News

Fentanyl: Potent Mu-Opioid Analgesia, Formulation Safety and Overdose Prevention

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians. Overview and mechanism Fentanyl is a highly potent synthetic phenylpiperidine opioid and full mu-opioid receptor agonist used by trained clinicians in anesthesia and selected severe-pain care. Activation of Gi/o-coupled mu receptors reduces…

Read Full News

Tramadol: Weak Mu Agonism, CYP2D6 Activation, Seizures and Serotonin Syndrome

Reviewed 10 November 2026 for medical education. This is not an individualized prescribing guide; refer to current local product labels and qualified clinicians. Overview and correct chemical class Tramadol is a synthetic cyclohexanol-derived centrally acting opioid analgesic, not a beta-substituted butyrophenone. It has weak parent-drug mu-opioid agonism and inhibits norepinephrine and serotonin reuptake. The O-desmethyltramadol…

Read Full News

Mefenamic Acid: Fenamate NSAID, Dysmenorrhea, Short-Course Dosing and Safety

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and chemical classification Mefenamic acid is an anthranilic acid-derived NSAID of the fenamate family, correctly named 2-[(2,3-dimethylphenyl)amino]benzoic acid. It reversibly inhibits cyclooxygenase COX-1 and COX-2, suppressing prostaglandin synthesis. The original monograph’s chemical name was inaccurate,…

Read Full News

Ketorolac: Pyrrolizine NSAID, Five-Day Limit, Renal Injury and Bleeding Warnings

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information. Overview and classification Ketorolac is a potent nonselective COX-1/COX-2-inhibiting NSAID derived from a pyrrolizine carboxylic acid structure, not an oxicam. It treats selected moderately severe acute pain requiring analgesia at the opioid level, often after surgery….

Read Full News